Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation

Acta Oncologica

Volumn 40, Issue 4, 2001, Pages 497-503

  Horsman, M R ^a   Murata, R ^a   Overgaard, J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; DRUG PRODUCTS; RADIOTHERAPY; THERMAL EFFECTS; TUMORS;

TUMOR GROWTH TIME;

ONCOLOGY;

MITOFLAXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BATH; BREAST CARCINOMA; CANCER CONTROL; CANCER RADIOTHERAPY; CHRONOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GROWTH RATE; HEATING; HYPERTHERMIC THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; STATISTICS; TEMPERATURE DEPENDENCE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FLAVONOIDS; FOOT; HYPERTHERMIA, INDUCED; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RADIOTHERAPY DOSAGE;

EID: 0034923996     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418601750288235     Document Type: Article

References (52)

1. Hyperthermia in the treatment of cancer
2. Thermal radiosensitization in animal tumors: The potential for therapeutic gain
3. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology
4. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer results from five randomized controlled trials
5. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy
6. Hyperthermia from the clinic to the laboratory: A hypothesis
7. Blood flow and heat transfer in Walker 256 mammary carcinoma
8. The role of blood flow in hyperthermia
9. Oxygen supply to malignant tissues
10. The relevance of tumor pH to the treatment of malignant disease
11. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro
12. Response of cells to hyperthermia under acute and chronic hypoxic conditions
13. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia
14. Hyperthermia in the treatment of tumors
15. The effect of vascular occlusion on the thermal sensitization of a mouse tumor
16. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-1 tumors
17. The effects of heat and radiation on cancers implanted on the feet of mice
18. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo
19. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor
20. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors
21. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour
22. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy
23. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy
24. Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action
25. Blood flow as a major determinant in the antitumour action of flavone acetic acid
26. The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo
27. The in vivo interaction between flavone acetic acid and hyperthermia
28. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice
29. Flavone acetic acid: A novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice
30. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid)
31. Flavone acetic acid (NSC 347512) induced haemorrhagic necrosis of mouse colon 26 and 28 tumours
32. Effect of flavone acetic acid on Lewis lung carcinoma: Evidence for an indirect effect
33. The use of vascularized spheroids to investigate the action of flavone acetic acid on tumour blood vessels
34. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma
35. Phase II trials with flavone acetic acid (NCS-347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma
36. Flavone acetic acid increases the antitumor effect of hyperthermia in mice
37. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo
38. Factors of importance for the development of the step-down heating effect in a C3H mammary carcinoma in vivo
39. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs
40. The use of hydralazine to manipulate tumour temperatures during hyperthermia
41. Rationale and problems in the design of clinical trials
42. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown
43. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid. (NSC 540488)
44. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid
45. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
46. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by the combination with 5-hydroxytryptamine and bioreductive drugs
47. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
48. Tumour vasculature as a target for cancer therapy
49. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid
50. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature
51. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
52. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid